KR101395377B1 - Ｈｉｖ 단백질 분해 효소 억제제 및 그를 포함하는 약학 조성물 - Google Patents

Ｈｉｖ 단백질 분해 효소 억제제 및 그를 포함하는 약학 조성물 Download PDF

Info

Publication number
KR101395377B1
KR101395377B1 KR1020137034899A KR20137034899A KR101395377B1 KR 101395377 B1 KR101395377 B1 KR 101395377B1 KR 1020137034899 A KR1020137034899 A KR 1020137034899A KR 20137034899 A KR20137034899 A KR 20137034899A KR 101395377 B1 KR101395377 B1 KR 101395377B1
Authority
KR
South Korea
Prior art keywords
compound
formula
reaction
solution
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137034899A
Other languages
English (en)
Korean (ko)
Other versions
KR20140021047A (ko
Inventor
켄네트 아르. 크라우포드
에릭 디. 도우디
아놀드 구티에레즈
리차드 피. 폴니아스제크
리차드 훙 치우 유
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20140021047A publication Critical patent/KR20140021047A/ko
Application granted granted Critical
Publication of KR101395377B1 publication Critical patent/KR101395377B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4084—Esters with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020137034899A 2006-03-29 2007-03-29 Ｈｉｖ 단백질 분해 효소 억제제 및 그를 포함하는 약학 조성물 Active KR101395377B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78712606P 2006-03-29 2006-03-29
US60/787,126 2006-03-29
PCT/US2007/007564 WO2007126812A2 (en) 2006-03-29 2007-03-29 Process for preparation of hiv protease inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087026569A Division KR101429300B1 (ko) 2006-03-29 2007-03-29 Ｈｉｖ 단백질 분해 효소 억제제의 제조 방법

Publications (2)

Publication Number Publication Date
KR20140021047A KR20140021047A (ko) 2014-02-19
KR101395377B1 true KR101395377B1 (ko) 2014-05-14

Family

ID=38323963

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137034899A Active KR101395377B1 (ko) 2006-03-29 2007-03-29 Ｈｉｖ 단백질 분해 효소 억제제 및 그를 포함하는 약학 조성물
KR1020087026569A Active KR101429300B1 (ko) 2006-03-29 2007-03-29 Ｈｉｖ 단백질 분해 효소 억제제의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087026569A Active KR101429300B1 (ko) 2006-03-29 2007-03-29 Ｈｉｖ 단백질 분해 효소 억제제의 제조 방법

Country Status (24)

Country Link
US (4) US8173623B2 (https=)
EP (2) EP1999133B1 (https=)
JP (2) JP5430395B2 (https=)
KR (2) KR101395377B1 (https=)
CN (2) CN101448838B (https=)
AP (2) AP2757A (https=)
AU (1) AU2007245194B2 (https=)
BR (1) BRPI0710199A2 (https=)
CA (1) CA2647316C (https=)
DK (1) DK1999133T3 (https=)
EA (2) EA016140B1 (https=)
ES (2) ES2430557T3 (https=)
HR (2) HRP20080554B1 (https=)
IL (2) IL194122A (https=)
MX (1) MX2008012398A (https=)
NO (2) NO342102B1 (https=)
NZ (2) NZ596074A (https=)
PL (1) PL1999133T3 (https=)
PT (1) PT1999133E (https=)
SG (1) SG170794A1 (https=)
SI (1) SI1999133T1 (https=)
UA (1) UA97241C2 (https=)
WO (1) WO2007126812A2 (https=)
ZA (1) ZA200808046B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
PL2528923T3 (pl) 2010-01-28 2015-01-30 Mapi Pharma Ltd Sposób wytwarzania darunawiru i pochodnych darunawiru
CN102190638A (zh) * 2010-03-16 2011-09-21 中国科学院上海药物研究所 联芳基醇二胺类化合物、其药物组合物、制备方法及应用
CN102584748B (zh) * 2011-01-13 2015-02-11 浙江九洲药业股份有限公司 夫沙那韦中间体的制备方法
EP2702045B1 (en) * 2011-04-26 2017-10-18 Mylan Laboratories Ltd. Novel process for the preparation of etravirine
EP2634180A1 (en) 2012-03-01 2013-09-04 Lonza Ltd. Enzymatic process for the preparation of butyrolactones
SI3333173T1 (sl) 2012-10-03 2019-08-30 Gilead Sciences, Inc. Postopki za pripravo analogov protivirusnega nukleotida
CN103664976B (zh) * 2013-12-12 2015-11-04 惠州市莱佛士制药技术有限公司 一种顺式六氢呋喃并[2,3-b]呋喃-3-醇的制备方法
EP3104712B1 (en) * 2014-02-12 2020-05-06 Firmenich Incorporated Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
JP6435907B2 (ja) * 2015-02-16 2018-12-12 住友化学株式会社 ヘキサヒドロフロフラノール誘導体の製造方法
CN108610227B (zh) * 2016-12-10 2021-02-09 中国科学院大连化学物理研究所 一种制备双环芳香化合物的方法
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121316A1 (en) 2002-04-26 2004-06-24 Gilead Sciences, Inc. Method and compositions for identifying anti-HIV therapeutic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6828894A (en) * 1993-05-14 1994-12-12 Merck & Co., Inc. Hiv protease inhibitors
AU1369001A (en) * 1995-12-13 2001-03-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP2314563A3 (en) 1999-12-23 2012-04-04 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
AU2002255473A1 (en) * 2000-10-24 2002-09-04 Glaxo Group Limited Process for preparing intermediates of hiv protease inhibitors
CN1561570A (zh) 2001-07-20 2005-01-05 皇家菲利浦电子有限公司 振荡电路、具有这种振荡电路的变换器以及具有这种变换器的预调节器
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US7273716B2 (en) * 2003-04-25 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121316A1 (en) 2002-04-26 2004-06-24 Gilead Sciences, Inc. Method and compositions for identifying anti-HIV therapeutic compounds

Also Published As

Publication number Publication date
NZ571302A (en) 2011-11-25
PL1999133T3 (pl) 2014-01-31
CA2647316C (en) 2013-05-28
EA020088B1 (ru) 2014-08-29
EA200802074A1 (ru) 2009-02-27
NO20180086A1 (no) 2008-12-22
US20080004242A1 (en) 2008-01-03
PT1999133E (pt) 2013-10-16
AP2008004641A0 (en) 2008-10-31
WO2007126812A3 (en) 2007-12-21
HRP20140626A2 (hr) 2014-11-07
NZ596074A (en) 2013-03-28
KR20080108322A (ko) 2008-12-12
IL225167A (en) 2016-03-31
HRP20080554B1 (hr) 2014-11-21
AU2007245194A1 (en) 2007-11-08
UA97241C2 (uk) 2012-01-25
CN101448838B (zh) 2012-07-04
SG170794A1 (en) 2011-05-30
EP2570416A1 (en) 2013-03-20
AP2013006690A0 (en) 2013-01-31
CN102516259A (zh) 2012-06-27
CN102516259B (zh) 2014-12-10
US8173623B2 (en) 2012-05-08
SI1999133T1 (sl) 2013-10-30
ES2572001T3 (es) 2016-05-27
JP5430395B2 (ja) 2014-02-26
CN101448838A (zh) 2009-06-03
EA016140B1 (ru) 2012-02-28
CA2647316A1 (en) 2007-11-08
US20120258935A1 (en) 2012-10-11
US8431745B2 (en) 2013-04-30
JP2013082717A (ja) 2013-05-09
ZA200808046B (en) 2009-06-24
EP1999133A2 (en) 2008-12-10
NO342102B1 (no) 2018-03-26
DK1999133T3 (da) 2013-11-25
US20130172295A1 (en) 2013-07-04
ES2430557T3 (es) 2013-11-21
NO342965B1 (no) 2018-09-10
BRPI0710199A2 (pt) 2012-03-06
AP2757A (en) 2013-09-30
JP2009531441A (ja) 2009-09-03
MX2008012398A (es) 2008-12-17
IL194122A (en) 2016-08-31
NO20084547L (no) 2008-12-22
KR101429300B1 (ko) 2014-08-11
WO2007126812A2 (en) 2007-11-08
HRP20080554A2 (hr) 2009-02-28
EA201100994A1 (ru) 2012-03-30
AU2007245194B2 (en) 2013-03-14
KR20140021047A (ko) 2014-02-19
US20110065631A1 (en) 2011-03-17
HK1180311A1 (en) 2013-10-18
HK1126756A1 (en) 2009-09-11
EP2570416B1 (en) 2016-03-16
EP1999133B1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
KR101395377B1 (ko) Ｈｉｖ 단백질 분해 효소 억제제 및 그를 포함하는 약학 조성물
CN115850304B (zh) 立体选择性制备2-烷基-4-硼基杂环类化合物的方法
KR100426030B1 (ko) 락톤계 당화합물에서의 키랄성 전환방법
JP2002536435A (ja) 非ヌクレオシド逆転写酵素インヒビター
KR100926844B1 (ko) 스핑고신의 합성을 위한 제조방법
US12344592B2 (en) Methods, processes and intermediates for preparing chroman compounds
RU2628081C2 (ru) Способы и промежуточные соединения для получения макроциклических ингибиторов протеазы hcv
WO2013105118A1 (en) A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
CN114269338A (zh) 生产二氮杂螺内酰胺化合物的方法和中间体
HK1180311B (en) Antiviral bisfuran derivative as hiv protease inhibitor and intermediates thereof
HK1126756B (en) Process for preparation of hiv protease inhibitors
CN115385951B (zh) 一种手性β-锗基-α-氨基酸及其合成方法
WO2010143150A2 (en) Process for stereoselective preparation of an intermediate of protease inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131230

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140124

Comment text: Request for Examination of Application

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140508

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140508

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170425

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170425

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180426

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180426

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190424

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190424

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200428

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210415

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220329

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230329

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20240328

Start annual number: 11

End annual number: 11